Skip to main content
Revive Therapeutics Ltd. logo

Revive Therapeutics Ltd. — Investor Relations & Filings

Ticker · RVV ISIN · CA7615161030 LEI · 967600MT7D67TXWXB884 CSE Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2025-05-12 Regulatory Filings
Country CA Canada
Listing CSE RVV

About Revive Therapeutics Ltd.

https://revivethera.com/

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases and rare disorders. The company's pipeline includes the investigation of Bucillamine for public health medical emergencies and rare inflammatory disorders, alongside the advancement of Psilocybin-based therapeutics. Revive prioritizes leveraging FDA regulatory incentives, such as Orphan Drug and Fast Track designations, to accelerate its drug development programs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 85% confidence The document is a corporate press release updating on a research study evaluating Bucillamine for nerve agent exposure. It contains no financial results, no meeting materials, no financing or M&A information, and no regulatory forms like 10-K or interim reports. It does not solicit votes or announce dividends. It is a general announcement to investors and the market, fitting the fallback category for miscellaneous regulatory announcements. Therefore, it is classified as a Regulatory Filing (RNS).
2025-05-12 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 87% confidence The document is a Canadian securities law form (Form 45-106F1 “Report of Exempt Distribution”), used to report the exemption‐based distribution of securities to regulators (SEDAR+). It is a statutory regulatory filing rather than a press release, investor presentation, or financial statement. There is no more specific category for NI 45-106 distribution reports, so it falls under the fallback “Regulatory Filings” (RNS).
2025-05-08 English
News release - English.pdf
Share Issue/Capital Change Classification · 90% confidence The document is a press release announcing a proposed shares-for-debt transaction whereby the company will issue new common shares to settle outstanding payables. This is a direct announcement of a new share issuance and capital structure change. It does not present full financial results or management commentary, nor is it a simple regulatory filing notice. Therefore, it fits the “Share Issue/Capital Change” category (SHA).
2025-04-21 English
News release - English.pdf
Regulatory Filings Classification · 35% confidence The document is a press release announcing a new research collaboration to investigate Bucillamine’s potential in cancer treatment. It does not present financial results, regulatory filings, voting outcomes, or any other specified report type; it is a general corporate announcement. Therefore, it falls under the fallback category of Regulatory Filings (RNS).
2025-04-10 English
News release - English.pdf
M&A Activity Classification · 85% confidence The document is a press release announcing Revive Therapeutics’ entry into an asset purchase agreement to acquire intellectual property and the issuance of shares as consideration. It describes the terms of an acquisition transaction rather than financial results, regulatory filings, or governance details. This falls squarely under M&A Activity.
2025-04-01 English
News release - English.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a press release announcing the voting results at Revive’s annual and special shareholder meeting held on March 18, 2025. It lists director elections and approved resolutions, which aligns with Declaration of Voting Results & Voting Rights announcements. Therefore, it should be classified as DVA.
2025-03-19 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.